Long-term dupilumab efficacy in type 2 asthma regardless of baseline characteristics

• Michael E. Wechsler,
• Linda Rogers,
• G. Walter Canonica,
• Arnaud Bourdin,
• Arman Altincatal,
• Megan Hardin,
• Xavier Soler,
• Paul J. Rowe,
• Yamo Deniz,
• Harry Sacks,
• Juby A. Jacob-Nara

Affiliations

Michael E. Wechsler

Department of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA

Linda Rogers

Icahn School of Medicine at Mount Sinai, New York, NY, USA

G. Walter Canonica

Department of Biomedical Sciences, Humanitas University, Milan, Italy

Arnaud Bourdin

Department of Respiratory Diseases, University of Montpellier, Montpellier, France

Arman Altincatal

Sanofi, Cambridge, MA, USA

Megan Hardin

Sanofi, Cambridge, MA, USA

Xavier Soler

Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA

Paul J. Rowe

Sanofi, Bridgewater, NJ, USA

Yamo Deniz

Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA

Harry Sacks

Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA

Juby A. Jacob-Nara

Sanofi, Bridgewater, NJ, USA